| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
|
N Engl J Med
|
2006
|
18.25
|
|
2
|
Routine early angioplasty after fibrinolysis for acute myocardial infarction.
|
N Engl J Med
|
2009
|
6.18
|
|
3
|
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
|
JAMA
|
2003
|
4.74
|
|
4
|
A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts.
|
N Engl J Med
|
2004
|
4.07
|
|
5
|
Assessing the association of appropriateness of coronary revascularization and clinical outcomes for patients with stable coronary artery disease.
|
J Am Coll Cardiol
|
2012
|
3.45
|
|
6
|
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).
|
J Am Coll Cardiol
|
2004
|
2.78
|
|
7
|
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
|
J Am Coll Cardiol
|
2007
|
2.56
|
|
8
|
Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial.
|
Circulation
|
2006
|
2.54
|
|
9
|
Effectiveness and safety of drug-eluting stents in Ontario.
|
N Engl J Med
|
2007
|
2.50
|
|
10
|
Impact of patient and target-vessel characteristics on arterial and venous bypass graft patency: insight from a randomized trial.
|
Circulation
|
2007
|
2.39
|
|
11
|
LARP7 is a stable component of the 7SK snRNP while P-TEFb, HEXIM1 and hnRNP A1 are reversibly associated.
|
Nucleic Acids Res
|
2008
|
2.38
|
|
12
|
A randomized comparison of intraoperative indocyanine green angiography and transit-time flow measurement to detect technical errors in coronary bypass grafts.
|
J Thorac Cardiovasc Surg
|
2006
|
2.35
|
|
13
|
Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.
|
J Virol
|
2009
|
2.35
|
|
14
|
Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis.
|
J Clin Invest
|
2003
|
2.21
|
|
15
|
HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase.
|
PLoS Pathog
|
2007
|
2.13
|
|
16
|
Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
|
PLoS Pathog
|
2010
|
2.12
|
|
17
|
Ontario multidetector computed tomographic coronary angiography study: field evaluation of diagnostic accuracy.
|
Arch Intern Med
|
2011
|
1.97
|
|
18
|
Productive human immunodeficiency virus type 1 assembly takes place at the plasma membrane.
|
J Virol
|
2007
|
1.66
|
|
19
|
Formation of mobile chromatin-associated nuclear foci containing HIV-1 Vpr and VPRBP is critical for the induction of G2 cell cycle arrest.
|
PLoS Pathog
|
2010
|
1.65
|
|
20
|
HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration.
|
J Neurosci
|
2007
|
1.64
|
|
21
|
HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing.
|
Blood
|
2009
|
1.63
|
|
22
|
Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes.
|
Arch Intern Med
|
2007
|
1.59
|
|
23
|
The impact of diabetic status on coronary artery bypass graft patency: insights from the radial artery patency study.
|
Circulation
|
2008
|
1.51
|
|
24
|
Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).
|
Eur Heart J
|
2011
|
1.49
|
|
25
|
Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum.
|
Retrovirology
|
2007
|
1.48
|
|
26
|
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
|
JAMA
|
2004
|
1.42
|
|
27
|
Efficacy and safety of a routine early invasive strategy after fibrinolysis stratified by glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: a pre-specified subgroup analysis of the TRANSFER-AMI randomised controlled trial.
|
Heart
|
2014
|
1.41
|
|
28
|
MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival.
|
FASEB J
|
2010
|
1.39
|
|
29
|
Radial artery and saphenous vein patency more than 5 years after coronary artery bypass surgery: results from RAPS (Radial Artery Patency Study).
|
J Am Coll Cardiol
|
2012
|
1.34
|
|
30
|
Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells.
|
J Biol Chem
|
2003
|
1.33
|
|
31
|
Assessment of the role of the central DNA flap in human immunodeficiency virus type 1 replication by using a single-cycle replication system.
|
J Virol
|
2004
|
1.19
|
|
32
|
The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone.
|
Am Heart J
|
2011
|
1.12
|
|
33
|
Role of CD4 receptor down-regulation during HIV-1 infection.
|
Curr HIV Res
|
2004
|
1.10
|
|
34
|
Determinants of variations in coronary revascularization practices.
|
CMAJ
|
2011
|
1.08
|
|
35
|
HIV-1 Vpr induces the K48-linked polyubiquitination and proteasomal degradation of target cellular proteins to activate ATR and promote G2 arrest.
|
J Virol
|
2010
|
1.08
|
|
36
|
Importin alpha3 interacts with HIV-1 integrase and contributes to HIV-1 nuclear import and replication.
|
J Virol
|
2010
|
1.07
|
|
37
|
Lentivirus Vpr and Vpx accessory proteins usurp the cullin4-DDB1 (DCAF1) E3 ubiquitin ligase.
|
Curr Opin Virol
|
2012
|
1.06
|
|
38
|
Quality of life after late invasive therapy for occluded arteries.
|
N Engl J Med
|
2009
|
1.06
|
|
39
|
HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface.
|
Traffic
|
2011
|
1.06
|
|
40
|
Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling.
|
J Virol
|
2012
|
1.05
|
|
41
|
Design of a trans protease lentiviral packaging system that produces high titer virus.
|
Retrovirology
|
2007
|
1.05
|
|
42
|
Contribution of the C-terminal tri-lysine regions of human immunodeficiency virus type 1 integrase for efficient reverse transcription and viral DNA nuclear import.
|
Retrovirology
|
2005
|
1.04
|
|
43
|
A late role for the association of hnRNP A2 with the HIV-1 hnRNP A2 response elements in genomic RNA, Gag, and Vpr localization.
|
J Biol Chem
|
2004
|
1.01
|
|
44
|
Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases.
|
Virology
|
2007
|
1.00
|
|
45
|
Major histocompatibility complex class II molecules promote human immunodeficiency virus type 1 assembly and budding to late endosomal/multivesicular body compartments.
|
J Virol
|
2006
|
0.98
|
|
46
|
Hypophosphorylation of poly(A) polymerase and increased polyadenylation activity are associated with human immunodeficiency virus type 1 Vpr expression.
|
Virology
|
2002
|
0.96
|
|
47
|
Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity.
|
PLoS One
|
2010
|
0.96
|
|
48
|
The evaluation of a formalized queue management system for coronary angiography waiting lists.
|
Can J Cardiol
|
2005
|
0.94
|
|
49
|
Recent advances in the understanding of HIV-1 Vpu accessory protein functions.
|
Curr Drug Targets Immune Endocr Metabol Disord
|
2004
|
0.94
|
|
50
|
Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress.
|
FASEB J
|
2011
|
0.91
|
|
51
|
Oral pathogens and allergic disease: results from the Third National Health and Nutrition Examination Survey.
|
J Allergy Clin Immunol
|
2006
|
0.90
|
|
52
|
HIV-1 viral protein R causes peripheral nervous system injury associated with in vivo neuropathic pain.
|
FASEB J
|
2010
|
0.90
|
|
53
|
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.
|
Am J Med
|
2002
|
0.90
|
|
54
|
Naturally-occurring genetic variants in human DC-SIGN increase HIV-1 capture, cell-transfer and risk of mother-to-child transmission.
|
PLoS One
|
2012
|
0.89
|
|
55
|
Thrombus aspiration during primary percutaneous coronary intervention is associated with reduced myocardial edema, hemorrhage, microvascular obstruction and left ventricular remodeling.
|
J Cardiovasc Magn Reson
|
2012
|
0.88
|
|
56
|
Synthesis of unsymmetrical 3,4-diaryl-3-pyrrolin-2-ones utilizing pyrrole Weinreb amides.
|
J Org Chem
|
2011
|
0.88
|
|
57
|
CD4 dimers constitute the functional component required for T cell activation.
|
J Immunol
|
2002
|
0.87
|
|
58
|
Interactions between human immunodeficiency virus (HIV)-1 Vpr expression and innate immunity influence neurovirulence.
|
Retrovirology
|
2011
|
0.87
|
|
59
|
Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses.
|
Am J Cardiol
|
2006
|
0.87
|
|
60
|
The tyrosine-based YXXØ targeting motif of murine leukemia virus envelope glycoprotein affects pathogenesis.
|
Virology
|
2004
|
0.86
|
|
61
|
Analysis of HIV-1 Vpr determinants responsible for cell growth arrest in Saccharomyces cerevisiae.
|
Retrovirology
|
2004
|
0.86
|
|
62
|
Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
|
Virus Res
|
2006
|
0.86
|
|
63
|
Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting.
|
Eur Heart J
|
2004
|
0.86
|
|
64
|
Association between disruption of CD4 receptor dimerization and increased human immunodeficiency virus type 1 entry.
|
Retrovirology
|
2006
|
0.84
|
|
65
|
Radial artery angiographic string sign: clinical consequences and the role of pharmacologic therapy.
|
Ann Thorac Surg
|
2006
|
0.83
|
|
66
|
A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting.
|
Can J Cardiol
|
2004
|
0.83
|
|
67
|
The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents.
|
Can J Cardiol
|
2007
|
0.83
|
|
68
|
Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.
|
J Biol Chem
|
2002
|
0.83
|
|
69
|
Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.
|
J Clin Microbiol
|
2002
|
0.82
|
|
70
|
Long-term safety and effectiveness of drug-eluting stents for the treatment of saphenous vein grafts disease: a population-based study.
|
JACC Cardiovasc Interv
|
2011
|
0.81
|
|
71
|
Cell context-dependent involvement of ATR in early stages of retroviral replication.
|
Virology
|
2009
|
0.81
|
|
72
|
Risk stratification, management and outcomes of patients with non-ST elevation acute coronary syndrome: a Canadian teaching hospital perspective.
|
Can J Cardiol
|
2003
|
0.81
|
|
73
|
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
|
JAMA
|
2002
|
0.81
|
|
74
|
Predictors of normal coronary arteries at coronary angiography.
|
Am Heart J
|
2013
|
0.81
|
|
75
|
Extracellular human immunodeficiency virus type 1 viral protein R causes reductions in astrocytic ATP and glutathione levels compromising the antioxidant reservoir.
|
Virus Res
|
2012
|
0.81
|
|
76
|
Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
|
Am J Cardiol
|
2005
|
0.81
|
|
77
|
Clinical outcomes and cost implications of routine early PCI after fibrinolysis: one-year follow-up of the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) study.
|
Am Heart J
|
2013
|
0.81
|
|
78
|
Effect of calcium-modulating cyclophilin ligand on human immunodeficiency virus type 1 particle release and cell surface expression of tetherin.
|
J Virol
|
2009
|
0.80
|
|
79
|
Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.
|
J Interv Cardiol
|
2003
|
0.80
|
|
80
|
Cardiovascular risk profiles and outcomes of Chinese living inside and outside China.
|
Eur J Cardiovasc Prev Rehabil
|
2010
|
0.80
|
|
81
|
Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices.
|
Am Heart J
|
2004
|
0.79
|
|
82
|
Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.
|
Am Heart J
|
2002
|
0.79
|
|
83
|
Contribution of the C-terminal region within the catalytic core domain of HIV-1 integrase to yeast lethality, chromatin binding and viral replication.
|
Retrovirology
|
2008
|
0.79
|
|
84
|
Modulation of allergic airway inflammation by the oral pathogen Porphyromonas gingivalis.
|
Infect Immun
|
2010
|
0.79
|
|
85
|
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
|
Circulation
|
2002
|
0.79
|
|
86
|
Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).
|
Am Heart J
|
2007
|
0.79
|
|
87
|
One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry.
|
Can J Cardiol
|
2010
|
0.79
|
|
88
|
Differential type 1 interferon-regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence.
|
FASEB J
|
2013
|
0.79
|
|
89
|
Takotsubo cardiomyopathy and left ventricular outflow tract obstruction.
|
J Interv Cardiol
|
2009
|
0.79
|
|
90
|
Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries.
|
J Am Coll Cardiol
|
2003
|
0.79
|
|
91
|
Clopidogrel in interventional cardiology: questions answered and questions remaining.
|
Can J Cardiol
|
2002
|
0.78
|
|
92
|
Viral protein R upregulates expression of ULBP2 on uninfected bystander cells during HIV-1 infection of primary CD4+ T lymphocytes.
|
Virology
|
2013
|
0.78
|
|
93
|
Two-step purification of His-tagged Nef protein in native condition using heparin and immobilized metal ion affinity chromatographies.
|
J Virol Methods
|
2003
|
0.77
|
|
94
|
Effect of bare metal stenting on angiographic and clinical outcomes in diabetic and nondiabetic patients undergoing percutaneous coronary intervention of nonacute occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA).
|
Catheter Cardiovasc Interv
|
2005
|
0.77
|
|
95
|
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
|
Contemp Clin Trials
|
2011
|
0.77
|
|
96
|
Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial.
|
Am Heart J
|
2012
|
0.76
|
|
97
|
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
|
Am Heart J
|
2005
|
0.76
|
|
98
|
Human immunodeficiency virus type 1 Vpr-mediated G(2) cell cycle arrest: Vpr interferes with cell cycle signaling cascades by interacting with the B subunit of serine/threonine protein phosphatase 2A.
|
EMBO J
|
2002
|
0.76
|
|
99
|
CD4/CXCR4 co-expression allows productive HIV-1 infection in canine kidney MDCK cells.
|
Virus Res
|
2006
|
0.76
|
|
100
|
Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study.
|
Cardiovasc Revasc Med
|
2012
|
0.76
|
|
101
|
Paclitaxel versus sirolimus stents in diabetic and nondiabetic patients.
|
Circ Cardiovasc Qual Outcomes
|
2009
|
0.76
|
|
102
|
New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu.
|
Retrovirology
|
2007
|
0.75
|
|
103
|
Thrombotic thrombocytopenic purpura associated with clopidogrel: further evaluation.
|
Can J Cardiol
|
2002
|
0.75
|
|
104
|
Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.
|
J Card Surg
|
2003
|
0.75
|
|
105
|
Clopidogrel and percutaneous coronary interventions.
|
JAMA
|
2003
|
0.75
|
|
106
|
Jean-Luc Darlix: Renaissance scientist and retrovirologist par excellence.
|
Retrovirology
|
2011
|
0.75
|
|
107
|
Low rates of angiographic and clinical restenosis with the new flexible MedStent for the treatment of single discrete coronary lesions.
|
J Interv Cardiol
|
2004
|
0.75
|
|
108
|
The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research.
|
J Virus Erad
|
2017
|
0.75
|
|
109
|
Indoleamine 2,3-Dioxygenase-Expressing Aortic Plasmacytoid Dendritic Cells Protect against Atherosclerosis by Induction of Regulatory T Cells.
|
Cell Metab
|
2016
|
0.75
|
|
110
|
Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: a subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).
|
Am Heart J
|
2012
|
0.75
|
|
111
|
Safety and effectiveness of drug-eluting stents among diabetic patients: a propensity analysis.
|
Am Heart J
|
2008
|
0.75
|
|
112
|
High mortality with ST elevation myocardial infarction in a nontrial setting.
|
Can J Cardiol
|
2004
|
0.75
|
|
113
|
Pharmacodynamic and clinical implications of switching between P2Y12 receptor antagonists: considerations for practice.
|
Crit Pathw Cardiol
|
2014
|
0.75
|
|
114
|
The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both?
|
Can J Clin Pharmacol
|
2004
|
0.75
|